Instituut voor Neuropathische Pijn
English articles Research & Development Flupirtine from CNSBio in neuropathic pain
| Flupirtine from CNSBio in neuropathic pain |
|
Flupirtine from CNSBio is in phase I for the development in neuropathic pain. However, flupirtine is an old molecule, aminopyridine. It has been used as an analgesic in the past and is still on the market in various countries.
Flupirtine is a centrally acting, non-opioid analgesic that is currently available in a number of European countries for the treatment of pain states. The compound has unique pharmacological properties. Flupiritine: mechanism of action and indicationsFlupirtine is an indirect NDMA receptor antagonist via its mechanism of action by activating potassium channels and it is characterized as a selective neuronal potassium channel opener. Various small-scale studies, together with extensive clinical experience, suggest that flupirtine effectively reduces chronic musculoskeletal pain, migraine and neuralgia. It also has muscle-relaxing effects and it can be combned with morphine as flupirtine increases the antinociceptive activity of morphine. Most common adverse effects associated with flupirtine use are drowsiness, dizziness, heartburn, dry mouth, fatigue and nausea. [1][2][3] Jan M. Keppel Hesselink, MD, PhD, september 2010 Referenties[1]: Devulder J. | Flupirtine in pain management: pharmacological properties and clinical use. | CNS Drugs. | 2010 Oct 1;24(10):867-81. doi: 10.2165/11536230-000000000-00000. [2]: Friedel HA, Fitton A. | Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. | Drugs. | 1993 Apr;45(4):548-69. [3]: McMahon FG, Arndt WF Jr, Newton JJ, Montgomery PA, Perhach JL. | Clinical experience with flupirtine in the U.S. | Postgrad Med J. | 1987;63 Suppl 3:81-5. |